Akari Therapeutics PLC

Akari Therapeutics PLC is an oncology company developing antibody-drug conjugates (ADCs) that deliver cancer-killing toxins. Its lead payload, PH1, is a spliceosome modulator designed to disrupt RNA splicing in cancer cells and trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate, AKTX-101, is a preclinical-stage trop2-targeting ADC that combines PH1 with a trop2 antibody to treat solid tumors, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, and prostate cancers. Akari Therapeutics is headquartered in Tampa, Florida.